Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biocruces Bizkaia (10)

2023

  1. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  2. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  3. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

    Molecular cancer, Vol. 22, Núm. 1, pp. 119

  4. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma

    Analytical Chemistry, Vol. 95, Núm. 4, pp. 2285-2293

2022

  1. PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer

    Oncogenesis, Vol. 11, Núm. 1

2021

  1. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  2. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

2020

  1. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2017

  1. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients

    PLoS ONE, Vol. 12, Núm. 8

2012

  1. The impact of peptidase activity on clear cell renal cell carcinoma survival

    American Journal of Physiology - Renal Physiology, Vol. 303, Núm. 12